Expression and biological characterization of an anti-CD20 biosimilar candidate antibody

A case study

Denise Dorvignit, Julio L. Palacios, Maylin Merino, Tays Hernández, Katya Sosa, Angel Casacó, Alejandro López-Requena and Cristina Mateo de Acosta*

1Immunobiology Department; Center of Molecular Immunology; Havana, Cuba; 2Development Department; Center of Molecular Immunology; Havana, Cuba; 3Center of Advanced Studies; Havana, Cuba; 4Clinical Trials Department; Center of Molecular Immunology; Havana, Cuba

Keywords: biosimilar antibody, Rituximab, cytotoxicity dependent complement, antibody-dependent mediated-cell cytotoxicity, apoptosis

Abbreviations: ch, chimeric antibody; mAb, monoclonal antibody; CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; PBMC, peripheral blood mononuclear cells; ABS, human AB serum; PI, propidium iodide

The CD20 molecule is a non-glycosylated protein expressed mainly on the surface of B lymphocytes. In some pathogenic B cells, it shows an increased expression, thus becoming an attractive target for diagnosis and therapy. Rituximab is a chimeric antibody that specifically recognizes the human CD20 molecule. This antibody is indicated for the treatment of non-Hodgkin lymphomas and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. In this work, we describe the stable expression and biological evaluation of an anti-CD20 biosimilar antibody. While rituximab is produced in fed-batch culture of recombinant Chinese hamster ovary (CHO) cells, our biosimilar antibody expression process consists of continuous culture of recombinant murine NS0 myeloma cells. The ability of the purified biosimilar antibody to recognize the CD20 molecule on human tumor cell lines, as well as on peripheral blood mononuclear cells from humans and primates, was demonstrated by flow cytometry. The biosimilar antibody induced complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and apoptosis on human cell lines with high expression of CD20. In addition, this antibody depleted CD20-positive B lymphocytes from peripheral blood in monkeys. These results indicate that the biological properties of the biosimilar antibody compare favorably with those of the innovator product, and that it should be evaluated in future clinical trials.

Introduction

Rituximab was the first mAb approved by United States Food and Drug Administration (US FDA) for malignant disease in 1997. This antibody recognizes human CD20, which is mainly expressed in B lymphocytes. It was first approved for non-Hodgkin lymphoma and more recently was approved in the US for rheumatoid arthritis, chronic lymphocytic leukemia, Wegener granulomatosis (WG) and microscopic polyangiitis. Rituximab has also been studied as a treatment for systemic lupus erythematosus with preliminary good results.

Studies in vitro have shown that rituximab is very effective in inducing complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The importance of CDC in vivo was demonstrated by Di Gaetano and colleagues by using mice deficient for complement component C1q. The authors have demonstrated the complete loss of rituximab activity in the absence of the γ chain of Fc receptors for IgG (FcγRs), which indicates the relevance of ADCC in the clinical outcome.

Apoptosis has been proposed as another mechanism for the antitumor activity of rituximab. Byrd et al. found that a group of B cell chronic lymphocytic leukemia patients treated with rituximab showed activation of caspase 9 and 3, which was associated with the elimination of malignant B lymphocytes. Moreover, rituximab caused a marked B-cell depletion in peripheral blood, bone marrow and lymphatic tissue when administered to Macaca fascicularis monkeys, although Vugmeyster et al. demonstrated that susceptibility to rituximab can differ on different B cells subsets in these monkeys.

Due to the positive results obtained with therapies using rituximab, a number of companies have considered commercialization of biosimilar versions of this antibody. For example, Dr. Reddy’s Laboratories produced a biosimilar variant of rituximab (trade name Reditux) even before the patent expiration date.

*Correspondence to: Cristina Mateo de Acosta; Email: cristina@cim.sld.cu
Submitted: 02/29/12; Revised: 05/14/12; Accepted: 05/15/12
http://dx.doi.org/10.4161/mabs.20761
Biosimilar antibodies must have the same amino acid sequence as the reference marketed product. However, because mAbs are large molecules with highly complex structures, the products are quite sensitive to a few changes in host cells, media and manufacturing process, which can influence on the biological activity.12,13

In this report, we describe the generation of biosimilar anti-CD20 rituximab by cloning of the genes encoding the variable regions of this antibody into expression vectors carrying constant region of IgG1 immunoglobulins.14 While rituximab is produced in fed-batch culture of recombinant Chinese hamster ovary (CHO) cells, our biosimilar antibody, 1B8, is expressed in continuous culture of murine NS0 myeloma cells. Because even minor structural changes, including the glycosylation pattern, can affect the safety, purity or potency of the recombinant protein, it is important to evaluate these differences. This antibody has been extensively studied using several analytical techniques (Romero et al. unpublished data) to identify potential changes in its structure with respect to the marketed rituximab product.

FDA and other regulatory agencies recommend using a stepwise approach to collecting the data and information needed to support a demonstration of biosimilarity. They suggest structural analysis, functional assays, determination of the mechanism of action, animal data and clinical studies. In this work, we focused on the expression and the functional characterization of the biosimilar anti-CD20 antibody. We demonstrated that biosimilar 1B8 mAb triggers similar CDC, ADCC and apoptosis mechanisms as commercial rituximab. Moreover, it depletes CD20-positive B lymphocytes from the peripheral blood of monkeys. Our results confirm that biosimilar mAbs with biological properties comparable to those of the reference marketed product can be successfully generated.

Results

Generation of anti-CD20 biosimilar mAb. A stable NS0 transfectoma expressing the anti-CD20 biosimilar was obtained, with a productivity of 20 μg/mL in batch culture. These cells showed a low level profile of intracellular IgG as analyzed by flow cytometry (Fig. 1A). To develop an industrial-grade cell line, adaptation to serum-free medium was performed. After cloning by limiting dilution, clone 1B8 was selected for its homogenous and high level expression of intracellular IgG (Fig. 1A). Then, 1B8 cells were inoculated into a bioreactor and the fermentation process followed for two months, with daily monitoring of growth, viability and chimeric antibody concentration in the supernatant. As shown in Figure 1B, viability remained invariant and close to 75%, while viable cell numbers (Xv) and IgG secretion increased in time.

Binding of biosimilar 1B8 mAb to CD20 molecule. The recognition of human CD20 molecule by biosimilar 1B8 mAb was evaluated by flow cytometry. Ramos, Daudi and Raji Burkitt’s lymphoma cell lines were used. As shown in Figure 2A, the biosimilar 1B8 mAb and rituximab share the recognition profile of CD20-positives cells. Raji cells showed the lowest MFI, while Daudi and Ramos cell displayed medium and high CD20 expression, respectively. Chronic myelogenous leukemia K-562 cells were used as negative control of CD20 expression, and chC5 mAb as isotype-matched control.

To determine the relative affinity of biosimilar 1B8 mAb with respect to rituximab, a competition assay was performed. Figure 2B shows that either unlabeled biosimilar 1B8 mAb or rituximab inhibited binding of biotinylated-rituximab to Ramos cells. The inhibition was dose-dependent and both antibodies reached more than 50% inhibition at the same concentration. ChC5 mAb was used as negative control.

Next, we evaluated binding of biosimilar 1B8 mAb to B lymphocytes from a healthy human donor and a Macaca fascicularis monkey. As shown in Figure 2C, there were no differences in the percentages of CD20-positive B cells recognized by biosimilar 1B8 mAb and rituximab in both species. Moreover, a non-B cell population was detected with low level of CD20. Ch1E10 mAb was used as negative control.
CDC induction by biosimilar 1B8 mAb. To test the capacity of biosimilar 1B8 mAb to trigger CDC, CD20-positive cell lines, Ramos, Daudi and Raji cells were incubated with the antibody and human AB serum as source of complement. Figure 3A shows that biosimilar 1B8 mAb induced a cytotoxic effect very similar to the one observed with rituximab. Lysis percentages correlated with the above determined CD20 levels indicated that Ramos cells were the most sensitive to CDC activity. ChC5 mAb control did not induce any cytotoxicity.

In addition, the antibody dose-dependence for CDC was evaluated. Different concentrations of both anti-CD20 antibodies were tested on Ramos cells. At concentrations as low as 0.025 μg/mL, a similar cytotoxic effect was detected for both anti-CD20 mAbs (Fig. 3B). Lysis at this concentration was about 40%, while it increased up to 80% when antibody concentration of 0.1 μg/mL or higher were used.

ADCC induction by biosimilar 1B8 mAb. The capacity of biosimilar 1B8 mAb to induce ADCC was assessed by determining the activity of cytosolic LDH released by treated Ramos cells. Different target:effector cell ratios were evaluated. Maximum Ramos cell lysis was reached with 1:50 ratio with about 80% of specific lysis (Fig. 4A).

The dose influence was then evaluated with the optimal 1:50 ratio. As shown in Figure 4B, the cytotoxic activity was demonstrated to be dose dependent. At concentrations as low as 0.32 ng/mL, the lysis was about 20%, while it increased up to 80% when antibody concentrations of 40 ng/mL or higher were used. Both anti-CD20 mAbs exhibited the same effect in all conditions.

Apoptosis induction by biosimilar 1B8 mAb. Phosphatidylserine exposure is an event that characterizes the early stages of apoptosis. Ramos cells were treated for 24 or 48 h with anti-CD20 mAbs and Annexin V-FITC and PI and analyzed by flow cytometry. Positive staining with FITC-labeled Annexin-V reflects a shift of phosphatidylserine from the inner to the outer layer of the cytoplasmic membrane. As shown in Figure 5A, the antibodies induced an increase of the percentage of cells with phosphatidylserine exposure on the outer leaflet of the cell membrane. This effect was almost three times higher in cells treated with biosimilar 1B8 mAb or rituximab in comparison with cells untreated or treated with the negative control antibody, and dependent on incubation time.

Because phosphatidylserine externalization can also occur in non-apoptotic events, the cleavage of caspase 3 as a late event in apoptosis was evaluated. During apoptosis, caspase 3 is processed into two fragments and the 17/19 kDa moiety was determined by a specific Alexa 488-conjugated antibody. Incubation of cells with biosimilar 1B8 mAb and rituximab for 48 h did not affect the cleavage of caspase 3 (Fig. 5B and upper part). Some studies have demonstrated that crosslinking of antigen-bound anti-CD20 antibody with a secondary antibody upregulates...
Figure 3. Induction of complement-dependent cytotoxicity (CDC) by biosimilar 1B8 mAb. (A) Human Burkitt’s lymphoma Daudi, Ramos and Raji cells were treated with 1 μg/mL of biosimilar 1B8 mAb for 2 h at 37°C. Human AB serum was used at 20%. Cell lysis was determined by PI uptake. (B) Dose-dependence for the induction of CDC by biosimilar 1B8 mAb on Ramos cells. Rituximab and isotype-matched chimeric C5 antibody were used as positive and negative controls, respectively. Results are representative of three independent experiments. AB-human AB serum.

Figure 4. Induction of antibody-dependent cell-mediated cytotoxicity (ADCC) by biosimilar 1B8 antibody. (A) Human Burkitt’s lymphoma Ramos cells were treated with 1 μg/mL of 1B8 mAb for 4 h at 37°C. PBMC from a healthy human donor were used as effector cells. Cytotoxicity was measured by a LDH-release assay. (B) Dose-dependence for the induction of ADCC by biosimilar 1B8 mAb on Ramos cells. Rituximab and isotype-matched chimeric C5 antibody were used as positive and negative controls, respectively. Results are representative of three independent experiments.

Fas expression, increases caspase activity and, in consequence, induces apoptosis in B-cell lines. The incubation of Ramos cells with biosimilar 1B8 mAb or rituximab in the presence of goat anti-human IgG increased the cleaved caspase 3 (Fig. 5B and lower part). There were no differences in the effect induced by both anti-CD20 mAbs.

Depletion of B lymphocytes in vivo induced by biosimilar 1B8 mAb. Finally, a critical point was to evaluate depletion of B lymphocytes induced by biosimilar 1B8 mAb. Macaca fascicularis monkey are widely used animal models in biomedical research, including studies of B cell targeting therapeutics. CD20-positive lymphocytes were evaluated before and after 1B8 (20 mg/Kg) administration. Figure 6A shows the administration schedule used. As shown in Figure 6B, CD20-positive B lymphocytes level decreased dramatically after first administration on day 4. These levels remained low until day 102, approximately two months after the last administration of this antibody. Recovery of CD20-positive B lymphocytes was observed from the fourth month, reaching the initial level about six months after last administration. There was no change in the percentage of CD20-positive T cells during this experiment. A representative result from each group is shown in Figure 6C.

Immunogenicity studies. The immunogenicity of biosimilar 1B8 mAb was determined through the measurement of
to finding effective therapies. Currently, conventional treatments such as chemotherapy, radiation and hormone therapy are also complemented with vaccines and mAbs, which are promising alternatives. Owing to the high price of these drugs, companies are commercializing these molecules after expiration of patents on the innovator product. Biosimilar antibodies must have the same amino acid sequence as the original immunoglobulins, but host cells, media or manufacturing processes are different and antibodies specific for the 1B8 F(ab')\textsubscript{2} fragment induced after its administration in monkeys. The anti-1B8 IgG response was detected only in two animals, with the highest levels at days 25 and 39 (Fig. 7).

**Discussion**

Cancer remains a serious health problem due to its high incidence and mortality, despite the substantial resources dedicated to finding effective therapies. Currently, conventional treatments such as chemotherapy, radiation and hormone therapy are also complemented with vaccines and mAbs, which are promising alternatives.

Owing to the high price of these drugs, companies are commercializing these molecules after expiration of patents on the innovator product. Biosimilar antibodies must have the same amino acid sequence as the original immunoglobulins, but host cells, media or manufacturing processes are different and
In this work, a strain producing an anti-CD20 biosimilar rituximab was obtained. The recombinant cell line secreting the chimeric antibody was selected based on both productivity and stability, for which it is important to isolate the subpopulation with the highest levels of sustained immunoglobulin secretion. Usually, during long-term cultures low-productivity subpopulation increases. Additionally, Sleiman and coworkers demonstrated the existence of a linear correlation, indirectly measured by reporter gene expression, between intracellular IgG and antibody specific production rate. Thus, for our selection process, we analyzed growth, productivity and intracellular IgG expression.

The starting transfectoma, cultured in medium supplemented with fetal bovine serum, produced 20 μg/mL in batch culture and showed predominance of a low intracellular IgG-containing subpopulation. After adaptation of serum-free conditions and cloning by limiting dilution, a clone with high intracellular IgG was selected. This clone, 1B8, was then seeded in a bioreactor to characterize the fermentation process for two months. Recombinant antibody secretion remained constant during this period. Our selection method, based on the determination of intracellular IgG content, thus successfully provided a high productivity strain.

We then assessed the biological activity of the biosimilar anti-CD20 antibody in comparison with the commercially available rituximab. As expected, biosimilar 1B8 mAb displayed the same recognition profile of CD20-positive cells line as rituximab, in which the binding strength correlated with the expression of CD20. Moreover, biosimilar 1B8 mAb inhibited the binding of rituximab to the cells as efficiently as the reference marketed product. We also evaluated the binding of biosimilar 1B8 mAb to B lymphocytes from a Macaca fascicularis monkey and a healthy human donor.

Rituximab has been demonstrated to exert its therapeutic action through different mechanisms, mainly CDC and, although still controversially, ADCC. ADCC is known to act synergistically with CDC on tumor cells through the ability of complement to promote inflammation and change the activation status of immune effector cells. These mechanisms are affected by the glycosylation pattern of the antibody Fc region due to the influence of carbohydrate moieties in the interaction with both complement proteins and Fcγ receptors on effector cells. As rituximab and biosimilar 1B8 mAb are obtained from different recombinant cell lines, it was mandatory to prove the capacity of the biosimilar antibody to mediate these cell-killing mechanisms. We therefore determined whether the ability of biosimilar 1B8 mAb to trigger CDC and ADCC was comparable to that of rituximab.

Biosimilar 1B8 mAb was as effective as rituximab in exerting CDC on human Burkitt’s lymphoma cells. As previously reported in reference 5, this effect was enhanced in cell lines with high CD20 expression. For ADCC, cell death was measured by cytosolic LDH release by target cells. This method is comparable with 51Cr-release assay and has been used for measuring this effect. Our results showed that ADCC induced by both anti-CD20 mAbs was similar, with the same dose-dependence and target:effector ratios.

Although the present results indicate that any differences in the glycosylation of the biosimilar antibody with respect to the marketed product due to the use of different expressing cell lines did not influence CDC and ADCC activities, characterization of the 1B8 glycosylation pattern is currently being completed (Romero et al. unpublished data).

Some reports suggest that rituximab does not have a significant apoptotic effect, but cross-linking of antigen-bound anti-CD20 antibody with a secondary antibody (hyper-cross-linking) enhances this activity. In vivo, hyper-cross-linking is thought to occur via engagement of Fc receptors. In this work, we determined the phosphatidylserine exposure on the cell membrane outer leaflet in cell treated with biosimilar 1B8 mAb as an indicator of early apoptosis. This phospholipid is exposed on the outer monolayer due to membrane depolarization in early apoptotic events. Both anti-CD20 mAbs induced the same effect on a Burkitt’s lymphoma cell line, even in the absence of hyper-cross-linking mAb, which agrees with Daniels et al.’s work with rituximab, and contrasts with those from other authors who have reported that apoptosis induced by rituximab cannot occur without the presence of secondary antibody. To further address the proapoptotic capacity of biosimilar 1B8 mAb, we assessed caspase 3 activation. Caspase 3 is partially or totally responsible for the product may have small physicochemical differences that need to be assessed, due to their potential impact on the biological activity of the antibody. A functional evaluation comparing both products could support a demonstration of biosimilarity and justify clinical testing with these antibodies.

![Figure 7. Immunogenicity of biosimilar 1B8 mAb in monkeys. Microtiter plates were coated with 3 μg/mL of 1B8 F(ab')2, fragment. IgG response for a serum dilution 1:1,000 was determined with an alkaline phosphatase-conjugated goat anti-human IgG (γ-chain specific) antibody. NT: non-treated animals.](image-url)
for the proteolytic activity of many key proteins involved in this mechanism.\textsuperscript{30} Frequently, this protein cleavage is measured as a late apoptotic event.\textsuperscript{28,31} Our results demonstrated the requirement of CD20-hyper-cross-linking in caspase 3 activation. These data are consistent with those from Jana et al. in which caspase 3 activation was observed in cells treated with rituximab in presence of secondary antibody. Furthermore, Byrd and coworkers demonstrated caspase 3 activation in primary tumors derived from rituximab-treated chronic lymphocytic leukemia patients.\textsuperscript{10}

After demonstrating that biosimilar 1B8 mAb was cytotoxic and proapoptotic, its capacity to eliminate B lymphocytes in vivo was evaluated as an approximation of its possible efficacy in patients. B cell depletion in rituximab-treated monkeys has been reported.\textsuperscript{4,11} Cynomolgus monkeys (Macaca fascicularis), whose B cells were recognized by biosimilar 1B8 mAb, were used in this study. Our data demonstrated that biosimilar 1B8 mAb depleted B lymphocytes from peripheral blood after the first administration. Interestingly, we found a non-B cell CD20-positive subpopulation. It has been demonstrated that the CD20 molecule is expressed, although to a lesser extent, in some T-cell subsets.\textsuperscript{1} Unlike B cells, this subpopulation with lower CD20-expression was not affected by biosimilar 1B8 mAb treatment. These results indicate a possible role for CDC in vivo, taking into account the differences in CD20 expression between both subpopulations. In fact, binding of C3b(i) to B cells from Macaca fascicularis monkeys following rituximab intravenous injection has been demonstrated.\textsuperscript{33}

1B8 mAb administration was safe and side effects were not observed in animals. Because biosimilar 1B8 mAb is a chimeric antibody, we decided to evaluate the immunogenicity corresponding to the variable region of this molecule. F(ab')\textsubscript{2} fragment was generated and the IgG response was evaluated in monkeys. Only two animals from the treated group had IgG response against 1B8 F(ab')\textsubscript{2} fragment; however, these antibodies did not impair the depleting effect of biosimilar 1B8 mAb.

In summary, this work reports the successful generation and biological characterization of an anti-CD20 biosimilar antibody. Our results provide evidence for the ability of biosimilar 1B8 mAb to eliminate CD20-positive B cells both in vitro and in vivo, which demonstrates the feasibility of the “biosimilar approach.” The scale-up of biosimilar 1B8 mAb production has been completed. A complete analysis, including full physical and chemical characterization of this antibody will be published. A clinical study in non-Hodgkin lymphoma patients was initiated and positive preliminary results have been observed.

**Materials and Methods**

**Cells.** The human Burkitt’s lymphoma cell lines Ramos, Daudi and Raji, murine myeloma NS0 and chronic myelogenous leukemia K-562 were purchased from American Type Culture Collection. Cells were cultured at 37°C and 5% CO\textsubscript{2} in RPMI 1640 or Dulbecco’s modified Eagles medium-F12 (DMEM-F12) medium supplemented with 2 mmol/L L-glutamine (Sigma-Aldrich, G7513) and 10% of heat-denatured fetal bovine serum (FBS; PAA, A15–211).

**Monoclonal antibodies.** Rituximab, a chimeric mAb that recognizes human CD20 molecule,\textsuperscript{4} was purchased from Roche (438219-1). Biosimilar 1B8 mAb was obtained in this work. Chimeric (human IgG1,κ) C5\textsuperscript{41} and 1E10\textsuperscript{30} mAbs were used as isotype-matched controls. The antibodies, together with biosimilar 1B8 mAb, were purified by Protein A Affinity Chromatography (GE-Healthcare, 17-5280-02) and analyzed by SDS-PAGE under reducing conditions. F(ab')\textsubscript{2} fragments were obtained using a standard procedure\textsuperscript{36} and were purified by size-exclusion high performance liquid chromatography (Sigma-Aldrich, TSK-G3000SWXL).

**Animals.** Macaca fascicularis monkeys (male and female, one to four years old) were purchased from the Center for Laboratory Animal Production (CENPALAB). Animal handling and experiments with the animals were performed in accordance with institutional guidelines.

**Vectors.** The pAH4604 and pAG4622 vectors, containing the human γ1 and κ constant regions, respectively, have been described previously in reference 14 and were kindly provided by Dr. Sherrie L. Morrison, Department of Microbiology and Molecular Genetics, UCLA.

**Variable region genes.** The genes of the rituximab light and heavy chain variable regions (V\textsubscript{L} and V\textsubscript{H}, respectively) were chemically synthesized (Geneart GmbH). The synthetic genes were excised by EcoRV/SalI (New England Biolabs, NEB, R0195L and R138L; V\textsubscript{L}) or EcoRV/NheI (NEB, R0131L, V\textsubscript{H}) digestion from Geneart vectors and cloned into pAG4622 and pAH4604, respectively.

**Chimeric antibody expression.** NS0 murine myeloma cells were co-transfected by electroporation with Petal-linearized pAG4622 and pAH4604, containing rituximab V\textsubscript{L} and V\textsubscript{H}, respectively, as previously in reference 14. DMEM-F12 containing 10% FBS and histidinol at 10 mM were used for the selection of antibody-producing transfecctomas. Chimeric antibody levels in the supernatants were quantified by enzyme-linked immunosorbent assay (ELISA), as previously in reference 37.

**Adaptation to serum-free medium and screening process.** The clone secreting the highest antibody levels secreting clone was grown in serum-free medium and scaled up for adaptation in the mixed CDM4NS0/DMEM-F12 1:1 (v:v) medium. After cloning by limiting dilution, intracellular IgG was analyzed by flow cytometry.

**Fermentation process.** 1B8 clone was grown in 15 L stirred tank bioreactors (Techfors HT, Infors AG CH-4103) in continuous culture. Bioreactor was seeded at 5 × 10\textsuperscript{6} cells/mL in the mixed CDM4NS0/DMEM-F12 1:1 (v:v) medium. To monitor cell density, viability and IgG concentration, samples (50 mL) were daily collected. Cells were counted in a Neubauer improved hemocytometer, cell concentration and viability was assessed by the trypan blue exclusion method and IgG concentration was determined by ELISA.\textsuperscript{37}

**mAb-biotin conjugation.** Antibodies (1 mg/mL) were dialyzed against borate buffer (0.1 M, pH 8.8) and incubated with 100 mg/mL of biotin N-hydroxysuccinimide ester (Sigma-Aldrich, H1759) for 4 h with gentle agitation at room temperature. Then, 20 μL of 1 M NH\textsubscript{4}Cl per 250 mg of biotin were
Isolation of PBMC. Peripheral blood mononuclear cells (PBMC) from healthy human donors and *Macaca fascicularis* monkeys were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE-Healthcare, 17-1440-02).

**Flow cytometry assays.** Mean fluorescence intensity (MFI) and percentage of stained cells were determined in a FACScan instrument (Becton Dickinson). The FlowJo 7.2.2 software (Tree Star) was used to analyze cells acquired on every fluorescence-activated cell sorting assay.

**Measurement of intracellular IgG.** NS0-transfected cells were fixed in ethanol for 2 h at -20°C and internal IgG content was determined with a fluorescein isothiocyanate (FITC)-conjugated goat anti-human polyclonal immunoglobulin antibody (Sigma Aldrich, F6506).

**Recognition of CD20 positive cells.** Ramos, Daudi, Raji and K562 cells (2 x 10⁵) were incubated with chimeric antibodies on ice for 30 min and washed with PBS. The binding of the antibodies was detected by incubation with a FITC-conjugated rabbit anti-human IgG F(ab')² (Dako, F0056) for 30 min on ice.

PBMC (5 x 10⁵) from a healthy human donor and a *Macaca fascicularis* monkey were incubated with biotinylated chimeric antibodies on ice for 30 min. After washing with PBS, the binding was detected with phycoerythrin (PE)-conjugated streptavidin (BD PharMingen, 554060). For the identification of the human and monkey B cell populations, the samples were labeled with FITC-conjugated goat anti-CD19 (AbD Serotec, MCA1940F) and anti-HLA DP, DQ, DR (BD PharMingen, 55558) antibodies, respectively. T-cell populations were stained with FITC-conjugated goat anti-CD4 (Dako, F0766) and CD8 (Dako, F0765) antibodies.

**Complement-dependent cytotoxicity.** Cells were incubated with chimeric mAbs for 2 h at 37°C in RPMI medium supplemented with bovine serum albumin (BSA) 1%. Human AB serum (ABS), from healthy donors, was used as the source of complement at 20%. Then, cells were washed, resuspended in PBS with propidium iodide (PI; Sigma-Aldrich, P4170) at 10 μg/mL and analyzed by flow cytometry. Dead cells were determined by scatter measurement (forward scatter and side scatter) and PI internalization. All cells that gated out of live cells and were PI-stained were considered dead.

**AnnexinV-FITC assay.** Annexin V was used to detect early stage apoptosis. Ramos cells (3 x 10⁴) were incubated with chimeric mAbs (3 μg/mL) for 24 or 48 h in RPMI medium supplemented with 2% FBS. Afterwards, cells were washed twice with AnnexinV binding buffer and incubated with AnnexinV-FITC and PI using manufacturer’s instructions (R&D System, TA5532).

**Caspase 3 activation.** Ramos cells (3 x 10⁣⁵) were incubated with chimeric mAbs (3 μg/mL) for 48 h in RPMI medium supplemented with 2% FBS. A goat anti-human IgG (γ-chain specific) antibody (final concentration 50 μg/mL; Sigma-Aldrich, Catalog #I3382) was used as crosslinker agent. Cells were washed with PBS and fixed and permeabilized with Cytofix/Cytoperm (BD PharMingen, 51-2090KZ). Then, cells were stained with an Alexa Fluor 488-conjugated goat anti-cleaved caspase 3 (Asp 175) antibody (Cell Signaling, 9669).

**Depletion and recovery of B lymphocytes in monkeys.** Two groups of five *Macaca fascicularis* monkeys each were treated either with six weekly intravenous doses of 20 mg/kg of biosimilar 1B8 mAb or 0.9% NaCl (control group). Blood was collected prior to the first administration, on day 11 and then every 14 d. Recovery of B lymphocytes was analyzed in blood taken approximately two, four and six months after the last dose of biosimilar 1B8 mAb. B cell percentage was determined by flow cytometry as described above.

**Monkey anti-chimeric antibody response.** Microtiter plates (Microlon 600, high binding, Greiner Bio-One GmbH, 655061) were coated overnight at 4°C with 3 μg/mL of 1B8 F(ab')² fragment in carbonate buffer at pH 9.6. After washing with PBS-Tween 20 0.05% (PBS-t), plates were blocked with PBS-t-BSA 1%, for 1 h at 37°C. After an incubation of 1 h at 37°C with diluted monkey sera (1:1,000), plates were washed and an alkaline phosphatase-conjugated goat anti-human IgG (γ-chain specific) antibody (Sigma-Aldrich, A3188) was added. After 1 h at 37°C, the reaction was developed with p-nitrophenylphosphate substrate (Sigma-Aldrich, N3254) solution and absorbance monitored at 405 nm in an ELISA reader ELX800 (DIALAB GmbH). Maximum release (high control) of LDH was determined in cells treated with 1% Triton X-100, while spontaneous release levels were measured in cells without antibody. Cells incubated with antibodies (low control) and effector cells alone were included as controls. The percentage of specific lysis was calculated according to the following formula:

\[
\text{Cytotoxicity (%)} = \frac{\{\text{[effector-target cell mix - effector cell control]} / \text{[low control]}\} \times 100}{\text{[high control - low control]}}
\]

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

This work was supported by the Center of Molecular Immunology.
11. Lupus erythematosus: lessons from therapy targeting light chain CDR1 of a humanized IgG1 antibody. Anal and characterization of asparagine deamidation in the mdr345. Lucas D, et al. The mechanism of tumor cell clearance by the therapeutic activity of rituximab in vivo. J Immunol 1993; 14:196-204; PMID:7679964; http://dx.doi.org/10.1016/j.jim.1975.02.09032.

12. Koopman G, Reutelingperger CP, Kuijten GA, Kehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-20; PMID:8060938.

13. Hofmeister JK, Cooney D, Coggleshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2004; 29:135-46; PMID:15705604; http://dx.doi.org/10.1016/j.bcmd.2004.06.027.

14. Coloma MJ, Hastings A, Winters LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992; 152:89-104; PMID:16400112; http://dx.doi.org/10.1016/0022-1759(92)90092-H.

15. Shi TX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Sunstrom NA. Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 2008; 99:578-87; PMID:17680677; http://dx.doi.org/10.1002/bt.21612.

16. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or Fab′2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 1997; 48:243-51; PMID:9823398; http://dx.doi.org/10.1002/1097-0142(199711)26:11<1169::AID-CLI2>3.0.CO;2-8.

17. Goly J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro. Blood 2000; 95:3900-8; PMID:10845926.

18. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17678100; http://dx.doi.org/10.1016/j.molimm.2007.06.015.

19. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007.

20. Kornienzki C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983; 64:313-20; PMID:6199426; http://dx.doi.org/10.1016/0022-1759(83)90438-6.

21. Shi TX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, et al. [Expression of CD16a in NK cells of B-cell non-Hodgkin’s lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng 2007; 26:837-42; PMID:17679754.

22. Wiznarska M, Wolny PM, Kelope T, Deo YM, Akebowski C, Hayes DF. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody. MDX-210. Breast Cancer Res Treat 1999; 53:199-207; PMID:10369066; http://dx.doi.org/10.1023/A:10155075677.

23. van der Kolk LE, Evers LM, Omenne C, Lena SM, Lederman S, van Lier RA, et al. CD20-induced cell death can bypass mitochondria and caspase activation. Leukemia 2002; 16:1753-4; PMID:12200688; http://dx.doi.org/10.1038/sj.lie.2102559.

24. Daniels I, Abulaya AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006; 11:1013-23; PMID:16544097; http://dx.doi.org/10.1007/s10495-006-6314-5.

25. Pedersen IM, Buhl AM, Klaussen P, Geiger CH, Juhlender J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99:1314-9; PMID:11839048; http://dx.doi.org/10.1182/blood.1994.11.1314.

26. Orlova I, Rizzardi G, Almenni ES, CPP32, a novel human apoptotic protein with homology to Casper/hibbrix/n elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994; 269:30671-4; PMID:7983002.

27. Iaziri AH, Huerta-Bayes S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role of sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65:264-76; PMID:15665303.

28. Janes E, Priest R, Wilde JJ, White JH, Malhotra R. Ritasum (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005; 139:439-46; PMID:15730389; http://dx.doi.org/10.1111/j.1365-2249.2005.02720.x.

29. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, et al. An anti-C3bi mAb enhances complement activation, C3bi deposition, and killing of CD20+ cells by rituximab. Blood 2003; 101:1071-9; PMID:12393727; http://dx.doi.org/10.1182/blood-2002-05-0876.

30. Roque-Navarro I, Marco C, Lombardero J, Muñoz G, Fernández A, Sosa K, et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomas 2003; 22:245-57; PMID:14531570; http://dx.doi.org/10.1089/153685903322328974.

31. López-Requena A, Mateo de Acosta C, Pérez A, Valle A, Lombardero J, Sosa K, et al. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunomoduline effects in their variable regions. Hybrid Hybridomas 2003; 22:235-43; PMID:14511569; http://dx.doi.org/10.1089/153685903322328965.

32. Coligan JEA, Margulies DH, Shevach EM, Strober W. Purification and fragmentation of antibodies. Current Protocols in Immunology, Wiley 1995; 1:285.

33. López-Requena A, De Acosta CM, Moreno E, Gonzalez M, Pachader Y, Talavera A, et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomas 2003; 22:245-57.; PMID:14531570; http://dx.doi.org/10.1089/153685903322328974.

34. Coligan JEA, Margulies DH, Shevach EM, Strober W. Purification and fragmentation of antibodies. Current Protocols in Immunology, Wiley 1995; 1:285.